^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Tazverik (tazemetostat) (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/25/2023
Excerpt:
Follicular Lymphoma….SECOND-LINE THERAPY FOR ELDERLY OR INFIRM….Other recommended regimens...Tazemetostat (irrespective of EZH2 mutation status)
